Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dyadic has entered into a research, development and licensing deal with an animal nutrition solutions provider (commercial partner) to develop, manufacture and commercialize animal feed enzyme products.
Subscribe to our email newsletter
The agreement allows the commercial partner to continue its research cooperation with Dyadic Netherlands, the R&D subsidiary of Dyadic.
Additionally, it will use Dyadic’s patented and proprietary C1 platform technology for the development of fungal strains that will produce high levels of enzymes for feed applications.
As per the agreement, the commercial partner has licensed Dyadic for using the developed C1 fungal strains for manufacturing and selling animal feed enzyme products.
Under the terms of the pact, the commercial partner is responsible to pay an upfront access fee to Dyadic and is also responsible to pay commercial milestone payment including royalties based on the its worldwide sales of products which utilize the C1 technology platform.
Dyadic president and CEO Mark Emalfarb said Dyadic has demonstrated and expects to continue to show the benefits of using Dyadic’s C1 technology for the development of novel highly productive and efficient animal feed enzyme products.
"This transaction is a prime example of Dyadic’s ability to leverage its technologies in a variety of industries by providing its partners with solutions that contribute to better performing products at higher productivity, lower costs and higher margins," Emalfarb said.